Literature DB >> 21545107

Synthesis and biological characterization of arylomycin B antibiotics.

Tucker C Roberts1, Peter A Smith, Floyd E Romesberg.   

Abstract

Antibiotics are virtually always isolated as families of related compounds, but the evolutionary forces underlying the observed diversity are generally poorly understood, and it is not even clear whether they are all expected to be biologically active. The arylomycin class of antibiotics is comprised of three related families that are differentiated by nitration, glycosylation, and hydroxylation of a conserved core scaffold. Previously, we reported the total synthesis of an A series member, arylomycin A2, as well as the A series derivative arylomycin C16 and showed that both are active against a broader spectrum of bacteria than previously appreciated. We now report the total synthesis of a B series analogue, arylomycin B-C16, and its aromatic amine derivative. While the aromatic amine loses activity against all bacteria tested, the B series compound shows activities that are similar to the A series compounds, except that it also gains activity against the important pathogen Streptococcus agalactiae.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21545107      PMCID: PMC3150569          DOI: 10.1021/np200163g

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  28 in total

1.  Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I.

Authors:  Palaniappan Kulanthaivel; Adam J Kreuzman; Mark A Strege; Matthew D Belvo; Tim A Smitka; Matthew Clemens; James R Swartling; Kristina L Minton; Feng Zheng; Eddie L Angleton; Deborah Mullen; Louis N Jungheim; Valentine J Klimkowski; Thalia I Nicas; Richard C Thompson; Sheng-Bin Peng
Journal:  J Biol Chem       Date:  2004-06-01       Impact factor: 5.157

Review 2.  Nitroaromatic compounds, from synthesis to biodegradation.

Authors:  Kou-San Ju; Rebecca E Parales
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

3.  Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations.

Authors:  Peter A Smith; Tucker C Roberts; Floyd E Romesberg
Journal:  Chem Biol       Date:  2010-11-24

4.  One pathway, many products.

Authors:  Michael A Fischbach; Jon Clardy
Journal:  Nat Chem Biol       Date:  2007-07       Impact factor: 15.040

5.  The frailty of adaptive hypotheses for the origins of organismal complexity.

Authors:  Michael Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

Review 6.  On the evolution of functional secondary metabolites (natural products).

Authors:  M J Stone; D H Williams
Journal:  Mol Microbiol       Date:  1992-01       Impact factor: 3.501

7.  Intramolecular Suzuki-Miyaura reaction for the total synthesis of signal peptidase inhibitors, arylomycins A(2) and B(2).

Authors:  Jeremy Dufour; Luc Neuville; Jieping Zhu
Journal:  Chemistry       Date:  2010-09-10       Impact factor: 5.236

8.  Crystallographic and biophysical analysis of a bacterial signal peptidase in complex with a lipopeptide-based inhibitor.

Authors:  Mark Paetzel; Jonathon J Goodall; Malgosia Kania; Ross E Dalbey; Malcolm G P Page
Journal:  J Biol Chem       Date:  2004-05-10       Impact factor: 5.157

9.  Biosynthetic origin of the rare nitroaryl moiety of the polyketide antibiotic aureothin: involvement of an unprecedented N-oxygenase.

Authors:  Jing He; Christian Hertweck
Journal:  J Am Chem Soc       Date:  2004-03-31       Impact factor: 15.419

10.  Structural and initial biological analysis of synthetic arylomycin A2.

Authors:  Tucker C Roberts; Peter A Smith; Ryan T Cirz; Floyd E Romesberg
Journal:  J Am Chem Soc       Date:  2007-12-01       Impact factor: 15.419

View more
  9 in total

Review 1.  Nonproteinogenic amino acid building blocks for nonribosomal peptide and hybrid polyketide scaffolds.

Authors:  Christopher T Walsh; Robert V O'Brien; Chaitan Khosla
Journal:  Angew Chem Int Ed Engl       Date:  2013-05-31       Impact factor: 15.336

2.  Type I signal peptidase and protein secretion in Staphylococcus aureus.

Authors:  Mark A Schallenberger; Sherry Niessen; Changxia Shao; Bruce J Fowler; Floyd E Romesberg
Journal:  J Bacteriol       Date:  2012-03-23       Impact factor: 3.490

3.  Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition.

Authors:  Peter A Smith; Floyd E Romesberg
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

4.  A putative cro-like repressor contributes to arylomycin resistance in Staphylococcus aureus.

Authors:  Arryn Craney; Floyd E Romesberg
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

Review 5.  Signal peptidase I: cleaving the way to mature proteins.

Authors:  Sarah M Auclair; Meera K Bhanu; Debra A Kendall
Journal:  Protein Sci       Date:  2011-11-22       Impact factor: 6.725

6.  Origins of Yersinia pestis sensitivity to the arylomycin antibiotics and the inhibition of type I signal peptidase.

Authors:  Danielle B Steed; Jian Liu; Elizabeth Wasbrough; Lynda Miller; Stephanie Halasohoris; Jeremy Miller; Brandon Somerville; Jeremy R Hershfield; Floyd E Romesberg
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

7.  Synthesis and characterization of the arylomycin lipoglycopeptide antibiotics and the crystallographic analysis of their complex with signal peptidase.

Authors:  Jian Liu; Chuanyun Luo; Peter A Smith; Jodie K Chin; Malcolm G P Page; Mark Paetzel; Floyd E Romesberg
Journal:  J Am Chem Soc       Date:  2011-10-14       Impact factor: 15.419

Review 8.  Polishing the tarnished silver bullet: the quest for new antibiotics.

Authors:  Mark A T Blaskovich; Mark S Butler; Matthew A Cooper
Journal:  Essays Biochem       Date:  2017-03-03       Impact factor: 8.000

Review 9.  Bacterial Signal Peptides- Navigating the Journey of Proteins.

Authors:  Sharbani Kaushik; Haoze He; Ross E Dalbey
Journal:  Front Physiol       Date:  2022-07-26       Impact factor: 4.755

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.